Email this page
Print
Bookmark and share
Bigger
Smaller
Download PDF
RSS feedFor consumers
(1300 633 424)
Mon-Fri | 9am-5pm AEST
Your call will be answered by healthdirect Australia
For health professionals
Find out the active ingredient and other brand names of your medicines with the NPS Medicine Name Finder
For a medicinewise Australia
Independent. Not-for-profit. Evidence based.
Site Tools
NPS RADAR April 2006NPS RADAR April 2006
NPS RADAR articles provide timely, independent, evidence-based assessment of new drugs, new PBS listings and research for health professionals.
Find out more about NPS RADAR.
| Title | Why read this |
|---|---|
| NPS RADAR April 2006 Professional publication - NPS RADAR - Complete issue | NPS RADAR articles provide timely, independent, evidence-based assessment of new drugs, new PBS listings and research for health professionals. |
| Fenofibrate (Lipidil) for dyslipidaemia Professional publication - NPS RADAR - Review | Reviews use of fenofibrate for dyslipidaemia, including comparison with gemfibrozil and monitoring for myopathy when used in combination with a statin. |
| Eplerenone (Inspra) for use after acute myocardial infarction complicated by heart failure Professional publication - NPS RADAR - Review | Reviews use of eplerenone for heart failure after acute myocardial infarction. Discusses the risk of hyperkalaemia and sex-hormone-related adverse effects. |
| Ezetimibe with simvastatin (Vytorin) Professional publication - NPS RADAR - Review | Ezetimibe with simvastatin (Vytorin) for dyslipidaemia |
Complete list of all NPS RADAR content.
Find out more about NPS RADAR.
Date published: 2006-04-01 00:00:00
Reasonable care is taken to provide accurate information at the date of creation. This information is not intended as a substitute for medical advice from a qualified health professional. Health professionals should rely on their own expertise and enquiries when providing medical advice or treatment. Where permitted by law, NPS disclaims all liability (including for negligence) for any loss, damage or injury resulting from reliance on or use of this information. Read our full disclaimer.
References to brands should not be taken as an endorsement by NPS.
